Literature DB >> 3137269

Increased frequency of HLA-DR2 in patients with autoantibodies to epidermolysis bullosa acquisita antigen: evidence that the expression of autoimmunity to type VII collagen is HLA class II allele associated.

W R Gammon1, E R Heise, W A Burke, J D Fine, D T Woodley, R A Briggaman.   

Abstract

Epidermolysis bullosa acquisita (EBA) is a chronic blistering disease characterized by circulating and tissue bound IgG auto-antibodies to the basement membrane zone (BMZ) of stratified squamous epithelium. Recent studies have shown that antibodies recognize epitopes present in the noncollagenous carboxyl-terminal domain of type VII collagen, a BMZ matrix protein. Antibodies with identical specificity also have been detected in patients with the rare blistering disease, bullous systemic lupus erythematosus (bullous SLE), suggesting EBA and bullous SLE are immunologically related diseases. In this study we determined the major histo-compatibility antigen types of 29 EBA patients and 6 patients with bullous SLE. Analysis of the results showed HLA-DR2 was significantly increased in both black EBA patients, P = 0.013 (corrected, RR = 4.8) and white EBA patients, P = 0.0008 (corrected, RR = 13.1). Five of the six bullous SLE patients also were positive for the DR2 antigen, P = 0.009. These results show the expression of autoimmunity to type VII collagen is HLA class II allele associated and that EBA and bullous SLE are immunogenetically related diseases.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3137269     DOI: 10.1111/1523-1747.ep12470317

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  15 in total

1.  Autoantibodies to type VII collagen have heterogeneous subclass and light chain compositions and their complement-activating capacities do not correlate with the inflammatory clinical phenotype.

Authors:  K Gandhi; M Chen; S Aasi; J C Lapiere; D T Woodley; L S Chan
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.317

Review 2.  Epidermolysis bullosa acquisita.

Authors:  Rishu Gupta; David T Woodley; Mei Chen
Journal:  Clin Dermatol       Date:  2012 Jan-Feb       Impact factor: 3.541

Review 3.  Epidermolysis bullosa acquisita: autoimmunity to anchoring fibril collagen.

Authors:  Mei Chen; Gene H Kim; Lori Prakash; David T Woodley
Journal:  Autoimmunity       Date:  2011-09-28       Impact factor: 2.815

4.  The cysteine-rich region of type VII collagen is a cystine knot with a new topology.

Authors:  Henrik Wegener; Hauke Paulsen; Karsten Seeger
Journal:  J Biol Chem       Date:  2014-01-02       Impact factor: 5.157

Review 5.  Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.

Authors:  Kyle T Amber; Dedee F Murrell; Enno Schmidt; Pascal Joly; Luca Borradori
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

Review 6.  Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations.

Authors:  Khalaf Kridin
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

7.  Molecular analysis of major histocompatibility complex alleles associated with the lupus anticoagulant.

Authors:  F C Arnett; M L Olsen; K L Anderson; J D Reveille
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

Review 8.  The Immunogenetics of Autoimmune Blistering Diseases.

Authors:  Diana Kneiber; Eric H Kowalski; Kyle T Amber
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 9.  Raising Awareness Among Healthcare Providers about Epidermolysis Bullosa and Advancing Toward a Cure.

Authors:  Aaron Tabor; Joseph V Pergolizzi; Guy Marti; John Harmon; Bernard Cohen; Jo Ann Lequang
Journal:  J Clin Aesthet Dermatol       Date:  2017-05-01

Review 10.  Autoimmunity to type VII collagen: epidermolysis bullosa acquisita.

Authors:  David T Woodley; Jennifer Remington; Mei Chen
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.